Health Innoventures venture capital fund




6/9/2008	Press Release - Achillion	Achillion Announces Additional Positive Top-Line Phase 2 Data for Elvucitabine
6/4/2008	Press Release - Achillion	Achillion Nominates ACH-1625 as Lead Candidate in Proprietary Program Targeting HCV Protease
5/13/2008	Press Release - PharmAthene	PharmAthene Reports First Quarter 2008 Financial Results
5/13/2008	Press Release - MiddleBrook Pharmaceuticals (formerly Advancis)	MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
5/12/2008	Press Release - Affymax	Affymax and Takeda Announce Long-Term Hematide Safety and Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney Disease Patients with Anemia




...is a venture capital fund that invests in innovative early to mid-stage companies that have the potential to deliver better medicines or deliver medicine better.

Please note that the Bear Stearns Privacy Policy and Disclaimer apply to this website